Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950123-07-003655
Filing Date
2007-03-13
Accepted
2007-03-12 17:38:50
Documents
5
Period of Report
2006-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K y31610e10vk.htm 10-K 895590
2 EX-23.1: CONSENT OF KOST, FORER, GABBAY & KASIERER y31610exv23w1.htm EX-23.1 2080
3 EX-31.1: CERTIFICATION y31610exv31w1.htm EX-31.1 7384
4 EX-31.2: CERTIFICATION y31610exv31w2.htm EX-31.2 7661
5 EX-32: CERTIFICATION y31610exv32.htm EX-32 4261
  Complete submission text file 0000950123-07-003655.txt   918406
Mailing Address 630 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10111
Business Address 630 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10111 (212) 887-6500
Omrix Biopharmaceuticals, Inc. (Filer) CIK: 0001349426 (see all company filings)

EIN.: 522147005 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-51905 | Film No.: 07688779
SIC: 2836 Biological Products, (No Diagnostic Substances)